Skip to main content

Virtual Incision Corporation, the developer of the MIRA™ Surgical System (MIRA), today announced data from its Investigational Device Exemption (IDE) clinical study has been published in Diseases of Colon and Rectum. The study was designed to assess the safety and efficacy of MIRA, the world’s first miniaturized robotic-assisted surgery device, in adults undergoing colectomy procedures. Results were provided to the Food and Drug Administration (FDA) as part of the submission to support the de novo marketing authorization of the device.

Read Article